Immunotherapeutic potential of anti-human endogenous retrovirus-k envelope protein antibodies in targeting breast tumors

Journal of the National Cancer Institute

Volumn 104, Issue 3, 2012, Pages 189-210

  Wang Johanning, Feng ^a,b,c   Rycaj, Kiera ^a,c   Plummer, Joshua B ^a,c   Li, Ming ^a,c   Yin, Bingnan ^a,c   Frerich, Katherine ^a   Garza, Jeremy G ^a   Shen, Jianjun ^b   Lin, Kevin ^b   Yan, Peisha ^d   Glynn, Sharon A ^e   Dorsey, Tiffany H ^e   Hunt, Kelly K ^b   Ambs, Stefan ^e   Johanning, Gary L ^a,c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 7; CASPASE 8; CASPASE 9; CELL DEATH INDUCING DFFA LIKE EFFECTOR A PROTEIN; CYCLIN DEPENDENT KINASE 5; CYCLIN DEPENDENT KINASE INHIBITOR 1A; FAS LIGAND; KI 67 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 6H5; PROTEIN; PROTEIN ANTIBODY; PROTEIN P53; RETROVIRUS K VIRUS ENVELOPE PROTEIN ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SIZE; CASE REPORT; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ADULT; AGED; ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; BROMODEOXYURIDINE; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; ENDOGENOUS RETROVIRUSES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDIES; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE EXPRESSION REGULATION, VIRAL; GENE PRODUCTS, ENV; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; IN SITU NICK-END LABELING; KI-67 ANTIGEN; MICE; MICE, NUDE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM GRADING; NEOPLASM STAGING; PILOT PROJECTS; PROTEIN ARRAY ANALYSIS; RANDOM ALLOCATION; RETROVIRIDAE PROTEINS; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84863177511     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr540     Document Type: Article

References (38)

1. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409(6822):860-921. (Pubitemid 32165345)
2. Cho K, Lee YK, Greenhalgh DG. Endogenous retroviruses in systemic response to stress signals. Shock. Aug;30(2):105-116.
3. Contreras-Galindo R, Kaplan MH, Leissner P, et al. Human endogenous retrovirus K (HML-2) elements in the plasma of people with lymphoma and breast cancer. J Virol. 2008;82(19):9329-9336.
4. Knossl M, Lower R, Lower J. Expression of the human endogenous retrovirus HTDV/HERV-K is enhanced by cellular transcription factor YY1. J Virol. 1999;73(2):1254-1261. (Pubitemid 29036779)
5. Ono M. Molecular cloning and long terminal repeat sequences of human endogenous retrovirus genes related to types A and B retrovirus genes. J Virol. 1986;58(3):937-944. (Pubitemid 16082783)
6. Mayer J, Sauter M, Racz A, Scherer D, Mueller-Lantzsch N, Meese E. An almost-intact human endogenous retrovirus K on human chromosome 7. Nat Genet. 1999;21(3):257-258. (Pubitemid 29124927)
7. Flockerzi A, Ruggieri A, Frank O, et al. Expression patterns of transcribed human endogenous retrovirus HERV-K(HML-2) loci in human tissues and the need for a HERV Transcriptome Project. BMC Genomics. 2008;9(Jul 29):354.
8. Kleiman A, Senyuta N, Tryakin A, et al. HERV-K(HML-2) GAG/ENV antibodies as indicator for therapy effect in patients with germ cell tumors. Int J Cancer. 2004;110(3):459-461. (Pubitemid 38649901)
9. Buscher K, Trefzer U, Hofmann M, Sterry W, Kurth R, Denner J. Expression of human endogenous retrovirus K in melanomas and melanoma cell lines. Cancer Res. 2005;65(10):4172-4180. (Pubitemid 40775655)
10. Seifarth W, Skladny H, Krieg-Schneider F, Reichert A, Hehlmann R, Leib-Mosch C. Retrovirus-like particles released from the human breast cancer cell line T47-D display type B-and C-related endogenous retroviral sequences. J Virol. 1995;69(10):6408-6416.
11. Etkind PR, Lumb K, Du J, Racevskis J. Type 1 HERV-K genome is spliced into subgenomic transcripts in the human breast tumor cell line T47D. Virology. 1997;234(2):304-308. (Pubitemid 27360122)
12. Ono M, Kawakami M, Ushikubo H. Stimulation of expression of the human endogenous retrovirus genome by female steroid hormones in human breast cancer cell line T47D. J Virol. 1987;61(6):2059-2062. (Pubitemid 17080235)
13. Ejthadi HD, Martin JH, Junying J, et al. A novel multiplex RT-PCR system detects human endogenous retrovirus-K in breast cancer. Arch Virol. 2005;150(1):177-184. (Pubitemid 40171959)
14. Wang-Johanning F, Frost AR, Johanning GL, et al. Expression of human endogenous retrovirus k envelope transcripts in human breast cancer. Clin Cancer Res. 2001;7(6):1553-1560. (Pubitemid 32708619)
15. Wang-Johanning F, Liu J, Rycaj K, et al. Expression of multiple human endogenous retrovirus surface envelope proteins in ovarian cancer. Int J Cancer. 2007;120(1):81-90. (Pubitemid 44901921)
16. Ruggieri A, Maldener E, Sauter M, et al. Human endogenous retrovirus HERV-K(HML-2) encodes a stable signal peptide with biological properties distinct from Rec. Retrovirology. 2009;6(Feb 16):17.
17. Wang-Johanning F, Frost AR, Jian B, Epp L, Lu DW, Johanning GL. Quantitation of HERV-K env gene expression and splicing in human breast cancer. Oncogene. 2003;22(10):1528-1535. (Pubitemid 36390602)
18. Wang-Johanning F, Radvanyi L, Rycaj K, et al. Human endogenous retrovirus K triggers an antigen-specific immune response in breast cancer patients. Cancer Res. 2008;68(14):5869-5877.
19. Golan M, Hizi A, Resau JH, et al. Human endogenous retrovirus (HERV-K) reverse transcriptase as a breast cancer prognostic marker. Neoplasia. 2008;10(6):521-533. (Pubitemid 351770296)
20. Prueitt RL, Boersma BJ, Howe TM, et al. Inflammation and IGF-I activate the Akt pathway in breast cancer. Int J Cancer. 2007;120(4):796-805. (Pubitemid 46175399)
21. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471-1474.
22. Sobin LH, Fleming ID. TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 1997;80(9):1803-1804.
23. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat. 1992;22(3):207-219.
24. Wang-Johanning F, Gillespie GY, Grim J, et al. Intracellular expression of a single-chain antibody directed against human papillomavirus type 16 E7 oncoprotein achieves targeted antineoplastic effects. Cancer Res. 1998;58(9):1893-1900. (Pubitemid 28217464)
25. Schmidt MM, Thurber GM, Wittrup KD. Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability. Cancer Immunol Immunother. 2008;57(12):1879-1890.
26. Rosenblum MG, Cheung LH, Liu Y, Marks JW III. Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin gelonin. Cancer Res. 2003;63(14):3995-4002. (Pubitemid 36917918)
27. Bikoue A, Janossy G, Barnett D. Stabilised cellular immuno-fluorescence assay: CD45 expression as a calibration standard for human leukocytes. J Immunol Methods. 2002;266(1-2):19-32. (Pubitemid 34804670)
28. Zhang Y, Wittner M, Bouamar H, Jarrier P, Vainchenker W, Louache F. Identification of CXCR4 as a new nitric oxide-regulated gene in human CD34+ cells. Stem Cells. 2007;25(1):211-219. (Pubitemid 46070113)
29. Glynn SA, Boersma BJ, Dorsey TH, et al. Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. J Clin Invest. 2010;120(11):3843-3854.
30. Moore PS, Chang Y. Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat Rev Cancer. 2010;10(12):878-889.
31. Benatti P, Basile V, Merico D, Fantoni LI, Tagliafico E, Imbriano C. A balance between NF-Y and p53 governs the pro-and anti-apoptotic transcriptional response. Nucleic Acids Res. 2008;36(5):1415-1428. (Pubitemid 351426096)
32. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol. 2008;9(5):402-412. (Pubitemid 351574202)
33. Ajay AK, Upadhyay AK, Singh S, et al. Cdk5 phosphorylates non-genotoxically overexpressed p53 following inhibition of PP2A to induce cell cycle arrest/apoptosis and inhibits tumor progression. Mol Cancer. 2010;9(Jul 31):204.
34. Maeda H, Akaike T. Nitric oxide and oxygen radicals in infection, inflammation, and cancer. Biochemistry (Mosc). 1998;63(7):854-865. (Pubitemid 128588115)
35. Ludwig DL, Pereira DS, Zhu Z, Hicklin DJ, Bohlen P. Monoclonal antibody therapeutics and apoptosis. Oncogene. 2003;22(56):9097-9106. (Pubitemid 38121710)
36. Hahn S, Ugurel S, Hanschmann KM, et al. Serological response to human endogenous retrovirus K in melanoma patients correlates with survival probability. AIDS Res Hum Retroviruses. 2008;24(5):717-723. (Pubitemid 351748779)
37. Avril N, Sassen S, Roylance R. Response to therapy in breast cancer. J Nucl Med. 2009;50(suppl 1):55S-63S.
38. Romanish MT, Cohen CJ, Mager DL. Potential mechanisms of endogenous retroviral-mediated genomic instability in human cancer. Semin Cancer Biol. 2010;20(4):246-253.